Latest news
Tecentriq, chemo combo approved in US for ES-SCLC
Tecentriq has been
approved in the US in combination with chemotherapy for the first-line
treatment of adults with extensive small cell lung cancer (ES-SCLC)....
In brief: Imara raises funds to advance sickle cell treatment
Massachusetts biopharma, Imara,
has raised $63 million in Series B funding to advance its treatment of sickle
cell disease.
Specifically,...
Orphan status for AstraZeneca’s potential IPF treatment
Saracatinib, a potential
new treatment from AstraZeneca for idiopathic pulmonary fibrosis (IPF), has
been granted Orphan Drug Designation (ODD) in the US.
